CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
Hye Ryeon Kim, Hyunji Jo, Hongsik Kim, Joohyun Hong, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Jin-Seok Ahn, Myung-Ju Ahn
Cancer Research and Treatment. 2023;55(1):344-349.   Published online 2022 March 26    DOI: https://doi.org/10.4143/crt.2021.1603

Excel Download

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
Cancer Research and Treatment. 2023;55(1):344-349   Crossref logo
Link1 Link2 Link3

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
Lung Cancer. 2017;114:68-69   Crossref logo
Link1 Link2

P76.87 Efficacy of Dacomitinib in EGFR TKI Refractory Metastatic Non-Small Cell Lung Cancer (EGFR Mutant) with Leptomeningeal Metastases
Journal of Thoracic Oncology. 2021;16(3):S627   Crossref logo
Link1 Link2

Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment
. 2019;   Crossref logo
Link1 Link2

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Annals of Oncology. 2020;31(10):1397-1404   Crossref logo
Link1 Link2

A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
Clinical Lung Cancer. 2021;22(4):376-380   Crossref logo
Link1 Link2

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
British Journal of Cancer. 2017;118(1):32-37   Crossref logo
Link1 Link2 Link3 Link4

P1.01-100 Effect of Osimertinib in Non-Small Cell Lung Cancer Patients with Brain Metastases After Progression Following Front-Line EGFR-TKI Therapy
Journal of Thoracic Oncology. 2019;14(10):S400   Crossref logo
Link1 Link2

Reversal of Acquired Resistance to EGFR–TKI in T790M-negative Patients With Non–small-cell Lung Cancer Using Anlotinib
. 2021;   Crossref logo
Link1 Link2

Osimertinib plus Bevacizumab Improve the Outcome of Leptomeningeal Metastasis Patients with EGFR Mutant Non-Small-Cell Lung Cancer
. 2022;   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.